Another big factor in all this IMO was the inability to recruit patients for the EMD AML trial which eventually morphed into cancelling the trial altogether due to RC220 becoming available some 12-18 months later. This all effectively set Race back approximately 2 years from where we were supposed to be with RC110 and lead to a "valley of death" situation which we're just coming out the other side of. Looking at a graph of the share price reflects descent into, and now out of, the valley of death almost perfectly.
On the plus side though, we've been through the pain and are now back on track with a far more valuable formulation than RC110 could ever have been.
Industry news, page-1739
-
- There are more pages in this discussion • 116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $276.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $456.4K | 284.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2659 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |